I型干扰素在感染与癌症中的作用：具有治疗意义的意外动态变化
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.
作者信息
Musella Martina, Manic Gwenola, De Maria Ruggero, Vitale Ilio, Sistigu Antonella
机构信息
Unit of Cellular Networks and Molecular Therapeutic Targets, Department of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy.
Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
出版信息
Oncoimmunology. 2017 Apr 5;6(5):e1314424. doi: 10.1080/2162402X.2017.1314424. eCollection 2017.
Abstract
If there is a great new hope in the treatment of cancer, the immune system is it. Innate and adaptive immunity either promote or attenuate tumorigenesis and so can have opposing effects on the therapeutic outcome. Originally described as potent antivirals, Type-I interferons (IFNs) were quickly recognized as central coordinators of tumor-immune system interactions. Type-I-IFNs are produced by, and act on, both tumor and immune cells being either host-protecting or tumor-promoting. Here, we discuss Type-I-IFNs in infectious and cancer diseases highlighting their dichotomous role and raising the importance to deeply understand the underlying mechanisms so to reshape the way we can exploit Type-I-IFNs therapeutically.
摘要
如果说癌症治疗有什么重大新希望的话，那就是免疫系统。固有免疫和适应性免疫既可以促进肿瘤发生，也可以减弱肿瘤发生，因此对治疗结果可能产生相反的影响。I型干扰素（IFNs）最初被描述为强效抗病毒物质，很快就被认为是肿瘤与免疫系统相互作用的核心协调因子。I型干扰素由肿瘤细胞和免疫细胞产生，并作用于这些细胞，既具有保护宿主的作用，也具有促进肿瘤的作用。在此，我们讨论I型干扰素在感染性疾病和癌症中的作用，强调其双重作用，并凸显深入了解其潜在机制以重塑我们利用I型干扰素进行治疗的方式的重要性。
相似文献
1
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.I型干扰素在感染与癌症中的作用：具有治疗意义的意外动态变化
Oncoimmunology. 2017 Apr 5;6(5):e1314424. doi: 10.1080/2162402X.2017.1314424. eCollection 2017.
2
Interferons, immunity and cancer immunoediting.干扰素、免疫与癌症免疫编辑
Nat Rev Immunol. 2006 Nov;6(11):836-48. doi: 10.1038/nri1961.
3
Double-edged effects of interferons on the regulation of cancer-immunity cycle.干扰素对癌症免疫循环调节的双刃剑效应。
Oncoimmunology. 2021 Jun 30;10(1):1929005. doi: 10.1080/2162402X.2021.1929005. eCollection 2021.
4
Role of interferons and other cytokines in the regulation of the immune response.干扰素及其他细胞因子在免疫反应调节中的作用。
APMIS. 1995 Mar;103(3):161-79. doi: 10.1111/j.1699-0463.1995.tb01092.x.
5
Lambda interferons in immunity and autoimmunity.λ 干扰素在免疫和自身免疫中的作用。
J Autoimmun. 2019 Nov;104:102319. doi: 10.1016/j.jaut.2019.102319. Epub 2019 Aug 31.
6
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation.I型干扰素在癌症促进和免疫激活中的阴阳两面。
Biology (Basel). 2021 Sep 1;10(9):856. doi: 10.3390/biology10090856.
7
Type I Interferons and Natural Killer Cell Regulation in Cancer.I型干扰素与癌症中的自然杀伤细胞调节
Front Immunol. 2017 Mar 31;8:304. doi: 10.3389/fimmu.2017.00304. eCollection 2017.
8
Type I interferons and dendritic cells in cancer immunotherapy.Ⅰ型干扰素与树突状细胞在癌症免疫治疗中的作用
Int Rev Cell Mol Biol. 2019;348:217-262. doi: 10.1016/bs.ircmb.2019.06.001. Epub 2019 Jun 20.
9
Antitumour actions of interferons: implications for cancer therapy.干扰素的抗肿瘤作用：对癌症治疗的启示。
Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14.
10
Type I interferons in anticancer immunity.I 型干扰素在癌症免疫中的作用。
Nat Rev Immunol. 2015 Jul;15(7):405-14. doi: 10.1038/nri3845. Epub 2015 Jun 1.
引用本文的文献
1
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.低强度I型干扰素信号传导促进CAR T细胞治疗疗效。
bioRxiv. 2025 May 20:2025.05.13.653878. doi: 10.1101/2025.05.13.653878.
2
FAM210B activates STAT1/IRF9/IFIT3 axis by upregulating IFN-α/β expression to impede the progression of lung adenocarcinoma.FAM210B通过上调IFN-α/β表达激活STAT1/IRF9/IFIT3轴，以阻碍肺腺癌的进展。
Cell Death Dis. 2025 Feb 3;16(1):63. doi: 10.1038/s41419-025-07375-9.
3
Phosphatidylserine (PS)-targeting chimeric Interferon (IFN) fusion proteins for anti-tumor applications.用于抗肿瘤应用的靶向磷脂酰丝氨酸（PS）的嵌合干扰素（IFN）融合蛋白。
bioRxiv. 2025 Jan 26:2025.01.24.634764. doi: 10.1101/2025.01.24.634764.
4
VAX014 Activates Tumor-Intrinsic STING and RIG-I to Promote the Development of Antitumor Immunity.VAX014激活肿瘤内在的STING和RIG-I以促进抗肿瘤免疫的发展。
Mol Cancer Ther. 2025 Apr 2;24(4):587-604. doi: 10.1158/1535-7163.MCT-24-0509.
5
Loss of increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration.[某种物质]的缺失通过增强免疫细胞浸润增加I型干扰素信号传导并减少胰腺肿瘤生长。
Front Immunol. 2025 Jan 10;15:1513595. doi: 10.3389/fimmu.2024.1513595. eCollection 2024.
6
Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases.伴有淋巴结转移的食管鳞状细胞癌的单细胞RNA测序和空间转录组学
Exp Mol Med. 2025 Feb;57(1):59-71. doi: 10.1038/s12276-024-01369-x. Epub 2025 Jan 1.
7
Updates in novel immunotherapeutic strategies for relapsed/refractory AML.复发/难治性急性髓系白血病新型免疫治疗策略的进展
Front Oncol. 2024 Dec 4;14:1374963. doi: 10.3389/fonc.2024.1374963. eCollection 2024.
8
Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.在分期匹配的结直肠癌中鉴定独特的免疫基因组基因特征
J Cancer Res Clin Oncol. 2024 Dec 14;151(1):9. doi: 10.1007/s00432-024-06034-4.
9
A STAT3-STING-IFN axis controls the metastatic spread of small cell lung cancer.STAT3-STING-IFN 轴控制小细胞肺癌的转移扩散。
Nat Immunol. 2024 Dec;25(12):2259-2269. doi: 10.1038/s41590-024-02014-5. Epub 2024 Nov 21.
10
LAMTOR1 ablation impedes cGAS degradation caused by chemotherapy and promotes antitumor immunity.LAMTOR1 缺失可阻碍化疗引起的 cGAS 降解，促进抗肿瘤免疫。
Proc Natl Acad Sci U S A. 2024 Oct 8;121(41):e2320591121. doi: 10.1073/pnas.2320591121. Epub 2024 Oct 3.
本文引用的文献
1
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.针对 CHK1 的治疗方法可耗尽 DNA 复制应激、p53 缺陷、超二倍体结直肠肿瘤干细胞。
Gut. 2018 May;67(5):903-917. doi: 10.1136/gutjnl-2016-312623. Epub 2017 Apr 7.
2
DNA Damage-Induced HSPC Malfunction Depends on ROS Accumulation Downstream of IFN-1 Signaling and Bid Mobilization.DNA 损伤诱导的 HSPC 功能障碍依赖于 IFN-1 信号转导和 Bid 动员下游的 ROS 积累。
Cell Stem Cell. 2016 Dec 1;19(6):752-767. doi: 10.1016/j.stem.2016.08.007. Epub 2016 Sep 15.
3
Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.热量限制模拟物增强抗癌免疫监视。
Cancer Cell. 2016 Jul 11;30(1):147-160. doi: 10.1016/j.ccell.2016.05.016.
4
EMT: 2016.EMT：2016 年。
Cell. 2016 Jun 30;166(1):21-45. doi: 10.1016/j.cell.2016.06.028.
5
The host STING pathway at the interface of cancer and immunity.癌症与免疫界面处的宿主STING通路。
J Clin Invest. 2016 Jul 1;126(7):2404-11. doi: 10.1172/JCI86892.
6
Type 1 Interferons Induce Changes in Core Metabolism that Are Critical for Immune Function.1型干扰素诱导对免疫功能至关重要的核心代谢变化。
Immunity. 2016 Jun 21;44(6):1325-36. doi: 10.1016/j.immuni.2016.06.006.
7
Antitumour actions of interferons: implications for cancer therapy.干扰素的抗肿瘤作用：对癌症治疗的启示。
Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14.
8
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.用水泡性口炎病毒和程序性死亡受体配体1（PD-L1）阻断剂进行免疫病毒疗法可提高小鼠急性髓系白血病的治疗效果。
Blood. 2016 Mar 17;127(11):1449-58. doi: 10.1182/blood-2015-06-652503. Epub 2015 Dec 28.
9
Immunometabolism governs dendritic cell and macrophage function.免疫代谢调控树突状细胞和巨噬细胞的功能。
J Exp Med. 2016 Jan 11;213(1):15-23. doi: 10.1084/jem.20151570. Epub 2015 Dec 22.
10
Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling.限制胆固醇生物合成通量会自发激活I型干扰素信号通路。
Cell. 2015 Dec 17;163(7):1716-29. doi: 10.1016/j.cell.2015.11.045. Epub 2015 Dec 10.
Zotero 插件